{"id":62261,"date":"2025-11-26T16:05:46","date_gmt":"2025-11-26T15:05:46","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/cleerly-unveils-powerscribe-integration-and-lesion-level-reporting-at-rsna-2025\/"},"modified":"2025-11-26T16:05:46","modified_gmt":"2025-11-26T15:05:46","slug":"cleerly-unveils-powerscribe-integration-and-lesion-level-reporting-at-rsna-2025","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/cleerly-unveils-powerscribe-integration-and-lesion-level-reporting-at-rsna-2025\/","title":{"rendered":"Cleerly Unveils PowerScribe Integration and Lesion-Level Reporting at RSNA 2025"},"content":{"rendered":"
\n

\nNew additions streamline data transfer with lesion details, helping make information more accessible for care teams<\/i>\n<\/p>\n

DENVER–(BUSINESS WIRE)–#AI<\/a>—Cleerly<\/a>, a leader in AI-based cardiovascular imaging, will showcase new product updates at RSNA 2025<\/a>, November 30 – December 4, 2025, at McCormick Place in Chicago, IL. At Booth #8039, Cleerly will demonstrate PowerScribe integration and newly added lesion-level reporting, discuss new clinical research findings, and provide guidance on the plaque analysis Category I CPT code effective January 1, 2026.\n<\/p>\n

<\/a>
<\/a>
<\/a>
<\/a><\/p>\n

\nThe PowerScribe integration will help simplify clinic workflows by mapping and transferring information from Coronary Computed Tomography Angiography (CCTA) reports to PowerScribe templates. This helps reduce manual data entry requirements and transcription errors, enabling efficient report generation and clinical documentation.\n<\/p>\n

\nThe updated lesion-specific details in the provider report provide clinical information about each identified lesion, giving providers comprehensive data with visual references to aid treatment planning. This anatomical detail can enable precise clinical decision-making based on morphological and compositional plaque characteristics at their fingertips.\n<\/p>\n

\nCleerly will also present new research at RSNA titled “Prognostic Utility of Coronary Calcification in the Consideration of Underlying Non-calcified Plaque Burden.” Presented by Dr. Parth Patel, the abstract offers new data comparing risk prediction of coronary artery calcium scores with non-calcified plaque volume using AI quantitative computed tomography (AI-QCT).\n<\/p>\n

\nCleerly representatives at RSNA will also be available to discuss the recently announced Final Rule for the Category I CPT code for plaque analysis (75577), which goes into effect January 1, 2026. The CY 2026 Physician Fee Schedule (PFS) Final Rule sets the global reimbursement rate at $1,026 for plaque analysis. Cleerly initiated this advancement by submitting an application to the American Medical Association’s CPT Editorial Panel in June 2024, and the Panel voted to accept the new code, elevating the technology from Category III to Category I status.\n<\/p>\n

\nVisit Cleerly at Booth #8039 during RSNA 2025<\/a> to experience these new product updates firsthand and learn more about the upcoming reimbursement changes. For more information, visit www.cleerlyhealth.com<\/a>.\n<\/p>\n

\nAbout Cleerly<\/b>\n<\/p>\n

\nCleerly is the company on a mission to eliminate heart attacks by creating a new standard of care for heart disease. Through its FDA-cleared solutions driven by artificial intelligence, Cleerly supports comprehensive phenotyping of coronary artery disease, as determined from advanced noninvasive CT imaging. Cleerly\u2019s approach is grounded in science, based on millions of images from over 40,000 patients. Led by a world-class clinical and technical team, Cleerly enhances health literacy for each and every stakeholder in the coronary care pathway. For more information, please visit: cleerlyhealth.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nCleerly Media Contact<\/b>
Christy Sievert
\n
press@cleerlyhealth.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

New additions streamline data transfer with lesion details, helping make information more accessible for care teams DENVER–(BUSINESS WIRE)–#AI—Cleerly, a leader in AI-based cardiovascular imaging, will showcase new product updates at RSNA 2025, November 30 – December 4, 2025, at McCormick Place in Chicago, IL. At Booth #8039, Cleerly will demonstrate PowerScribe integration and newly added … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-62261","6":"format-standard","7":"category-industry"},"yoast_head":"\nCleerly Unveils PowerScribe Integration and Lesion-Level Reporting at RSNA 2025 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/cleerly-unveils-powerscribe-integration-and-lesion-level-reporting-at-rsna-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cleerly Unveils PowerScribe Integration and Lesion-Level Reporting at RSNA 2025 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"New additions streamline data transfer with lesion details, helping make information more accessible for care teams DENVER–(BUSINESS WIRE)–#AI—Cleerly, a leader in AI-based cardiovascular imaging, will showcase new product updates at RSNA 2025, November 30 – December 4, 2025, at McCormick Place in Chicago, IL. At Booth #8039, Cleerly will demonstrate PowerScribe integration and newly added ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/cleerly-unveils-powerscribe-integration-and-lesion-level-reporting-at-rsna-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-26T15:05:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20251126703383\/en\/2654765\/22\/cleerly_pr_new-reporting-rsna.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cleerly-unveils-powerscribe-integration-and-lesion-level-reporting-at-rsna-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cleerly-unveils-powerscribe-integration-and-lesion-level-reporting-at-rsna-2025\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Cleerly Unveils PowerScribe Integration and Lesion-Level Reporting at RSNA 2025\",\"datePublished\":\"2025-11-26T15:05:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cleerly-unveils-powerscribe-integration-and-lesion-level-reporting-at-rsna-2025\\\/\"},\"wordCount\":427,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cleerly-unveils-powerscribe-integration-and-lesion-level-reporting-at-rsna-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251126703383\\\/en\\\/2654765\\\/22\\\/cleerly_pr_new-reporting-rsna.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cleerly-unveils-powerscribe-integration-and-lesion-level-reporting-at-rsna-2025\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cleerly-unveils-powerscribe-integration-and-lesion-level-reporting-at-rsna-2025\\\/\",\"name\":\"Cleerly Unveils PowerScribe Integration and Lesion-Level Reporting at RSNA 2025 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cleerly-unveils-powerscribe-integration-and-lesion-level-reporting-at-rsna-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cleerly-unveils-powerscribe-integration-and-lesion-level-reporting-at-rsna-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251126703383\\\/en\\\/2654765\\\/22\\\/cleerly_pr_new-reporting-rsna.jpg\",\"datePublished\":\"2025-11-26T15:05:46+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cleerly-unveils-powerscribe-integration-and-lesion-level-reporting-at-rsna-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cleerly-unveils-powerscribe-integration-and-lesion-level-reporting-at-rsna-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cleerly-unveils-powerscribe-integration-and-lesion-level-reporting-at-rsna-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251126703383\\\/en\\\/2654765\\\/22\\\/cleerly_pr_new-reporting-rsna.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251126703383\\\/en\\\/2654765\\\/22\\\/cleerly_pr_new-reporting-rsna.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cleerly-unveils-powerscribe-integration-and-lesion-level-reporting-at-rsna-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cleerly Unveils PowerScribe Integration and Lesion-Level Reporting at RSNA 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cleerly Unveils PowerScribe Integration and Lesion-Level Reporting at RSNA 2025 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/cleerly-unveils-powerscribe-integration-and-lesion-level-reporting-at-rsna-2025\/","og_locale":"en_US","og_type":"article","og_title":"Cleerly Unveils PowerScribe Integration and Lesion-Level Reporting at RSNA 2025 - Pharma Trend","og_description":"New additions streamline data transfer with lesion details, helping make information more accessible for care teams DENVER–(BUSINESS WIRE)–#AI—Cleerly, a leader in AI-based cardiovascular imaging, will showcase new product updates at RSNA 2025, November 30 – December 4, 2025, at McCormick Place in Chicago, IL. At Booth #8039, Cleerly will demonstrate PowerScribe integration and newly added ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/cleerly-unveils-powerscribe-integration-and-lesion-level-reporting-at-rsna-2025\/","og_site_name":"Pharma Trend","article_published_time":"2025-11-26T15:05:46+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20251126703383\/en\/2654765\/22\/cleerly_pr_new-reporting-rsna.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/cleerly-unveils-powerscribe-integration-and-lesion-level-reporting-at-rsna-2025\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/cleerly-unveils-powerscribe-integration-and-lesion-level-reporting-at-rsna-2025\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Cleerly Unveils PowerScribe Integration and Lesion-Level Reporting at RSNA 2025","datePublished":"2025-11-26T15:05:46+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/cleerly-unveils-powerscribe-integration-and-lesion-level-reporting-at-rsna-2025\/"},"wordCount":427,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/cleerly-unveils-powerscribe-integration-and-lesion-level-reporting-at-rsna-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20251126703383\/en\/2654765\/22\/cleerly_pr_new-reporting-rsna.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/cleerly-unveils-powerscribe-integration-and-lesion-level-reporting-at-rsna-2025\/","url":"https:\/\/pharma-trend.com\/en\/cleerly-unveils-powerscribe-integration-and-lesion-level-reporting-at-rsna-2025\/","name":"Cleerly Unveils PowerScribe Integration and Lesion-Level Reporting at RSNA 2025 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/cleerly-unveils-powerscribe-integration-and-lesion-level-reporting-at-rsna-2025\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/cleerly-unveils-powerscribe-integration-and-lesion-level-reporting-at-rsna-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20251126703383\/en\/2654765\/22\/cleerly_pr_new-reporting-rsna.jpg","datePublished":"2025-11-26T15:05:46+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/cleerly-unveils-powerscribe-integration-and-lesion-level-reporting-at-rsna-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/cleerly-unveils-powerscribe-integration-and-lesion-level-reporting-at-rsna-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/cleerly-unveils-powerscribe-integration-and-lesion-level-reporting-at-rsna-2025\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20251126703383\/en\/2654765\/22\/cleerly_pr_new-reporting-rsna.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20251126703383\/en\/2654765\/22\/cleerly_pr_new-reporting-rsna.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/cleerly-unveils-powerscribe-integration-and-lesion-level-reporting-at-rsna-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Cleerly Unveils PowerScribe Integration and Lesion-Level Reporting at RSNA 2025"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62261","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=62261"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62261\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=62261"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=62261"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=62261"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}